Cencora (COR) Q4 2025 10-Q Quarterly Report
Filed: Feb 4, 2026Period ending Dec 31, 2025
Consumer Staples
Wholesale-Drugs, Proprietaries & Druggists' SundriesSEC EDGAR Cencora (COR) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Feb 4, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Cencora Q4 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $85.9B, up 5.5% YoY (+$4.4B); U.S. Healthcare Solutions +5.0% ($3.7B), International Healthcare Solutions +9.6% ($0.7B)
- • Gross profit $3.07B, up 20.1% YoY; U.S. Healthcare Solutions margin 2.47% (+46 bps), International Healthcare Solutions +3.3% gross profit increase
Risk Factors
- • No material changes in risk factors compared to 10-K for fiscal year ended September 30, 2025
- • Carried-forward regulatory risk: potential impact of evolving healthcare laws on pricing and reimbursement policies
Cencora Q4 2025 Quarterly FinancialsXBRL
Revenue
$85.9B
▲ +5.5% YoY
Net Income
$560M
▲ +14.5% YoY
Gross Margin
3.6%
▲ +44bp YoY
Operating Margin
0.9%
▲ +2bp YoY
Net Margin
0.7%
▲ +5bp YoY
ROE
29.3%
▼ -18631bp YoY
Total Assets
$78.4B
▲ +13.5% YoY
EPS (Diluted)
$2.87
▲ +14.8% YoY
Operating Cash Flow
-$2.3B
▲ +15.2% YoY
Source: XBRL data from Cencora Q4 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Cencora
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.